Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.

Chunguang Xia

Xiquan Zhang

Aiming Zhang

Lin Liu

Guangming Sang

Xiaopeng Guo

Rui Zhao

Gang Wu

Xingdong Cheng

Jiabin Qiao

Qide Li

Lang Chen

Xingjian Zhou

Ce Gao

The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and performing further reaction to obtain trifluridine.

Method for preparing trifluridine

The present application relates to a method for preparing a cholic acid compound. Specifically, the method prepares a compound as shown in formula I, including subjecting a compound of formula 2 to an oxidization reaction to obtain a compound of formula 3; attaching a trimethylsilyl group to the compound of formula 3 to obtain a compound of formula 4; reacting the compound of formula 4 with acetaldehyde to obtain a compound of formula 5; subjecting the compound of formula 5 to a catalytic hydrogenation reaction to obtain a compound of formula 6; and converting a cyano group of the compound of formula 6 to a carboxyl group to give the compound of formula I. 

Method for preparing cholic acid compound

The present application relates to a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the salt thereof, a crystal comprising the compound represented by Formula (I), a crystal composition comprising the crystal of the salt thereof, a pharmaceutical composition thereof, and medical uses thereof. 

Crystal of DPP-IV long-acting inhibitor and salt

The present invention relates to a crystalline form of tenofovir dipivoxil fumarate, a crystalline composition and a pharmaceutical composition comprising the crystalline form, and also to a process for preparing the same and the use for prophylaxis or treatment of a disease associated with a viral infection. The crystalline form has an X-ray powder diffraction pattern using Cu-K&#x3b1; radiation, expressed in terms of lattice spacing 'd' comprising peaks at about 18.4714 &#x212b;, 5.0350 &#x212b;, 4.6380 &#x212b;, 4.5347 &#x212b;, 4.3838 &#x212b;, 4.2874 &#x212b; and 3.6304 &#x212b;.

Crystalline forms of tenofovir dipivoxil fumarate

Growing community of inventors

Jiangsu, China

Chunguang Xia